NASDAQ:RNTX
Rein Therapeutics, Inc.
Rein Therapeutics, Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 41.8%.Summary generated from Rein Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−139.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+41.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −27 | −28 | −16 | −65 | −51 |
| Net income | −26 | −27 | −16 | −63 | −50 |
| Free cash flow | −24 | n/a | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 4, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of a shareholder vote
Jul 21, 2026 - DEF 14AProxy statement
Jun 8, 2026 - 4Insider transaction report
May 28, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 4Insider transaction report
May 13, 2026